Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Gray zone lymphoma: pembrolizumab

Fernando Barroso Duarte • 20 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Hodgkin Lymphoma Lymphoma Antibodies Pembrolizumab

Dr Fernando Barroso Duarte, MD, Federal University of Ceara, Clinical Hospital, Fortaleza, Brazil, discusses the use of checkpoint inhibitors, including pembrolizumab in gray zone lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fernando Barroso Duarte

6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
3:31
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era
Fernando Barroso Duarte • 13 Feb 2023
4:11
Expanding access to stem cell transplantation & CAR-T therapy in Latin America
Fernando Barroso Duarte • 13 Feb 2023
2:26
Aims & activity of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO)
Fernando Barroso Duarte • 13 Feb 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals